Verastem (VSTM) Misses Q1 EPS by 5c, Revenues Miss; FY19 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Verastem Oncology Reports First Quarter 2019 Financial Results
May 9, 2019 4:05 PM EDTCompany Reports $1.7 Million in Net Product Revenues from COPIKTRA; Issues Product Revenue Guidance for 2019
Cash, Cash Equivalents and Short-Term Investments of $211.7 Million as of March 31, 2019
Company to Host Conference Call Today at 4:30 PM ET
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology, (or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today reported financial results for the three months ended March 31, 2019.
We are now into the... More
